[1]Khalilzadeh O, Noshad S, Rashidi A, et al. Graves’ophthalmopathy: a review of immunogenetics [J]. Curr Genomics, 2011, 12(8):564-575. [2]Bahn RS. Graves’ ophthalmopathy [J]. N Engl J Med, 2010, 362(8):726-738. [3]Bartley GB, Fatourechi V, Kadrmas EF, et al.Clinical features of Graves’ ophthalmopathy in an incidence cohort [J]. Am J Ophthalmol, 1996, 121(3):284-290. [4]Kirsch E, Hammer B, von Arx G. Graves’ orbitopathy: current imaging procedures [J]. Swiss Med Wkly, 2009, 139(43-44):618-623. [5]Kirsch E, von Arx G, Hammer B. Imaging in Graves’ orbitopathy [J]. Orbit, 2009, 28(4):219-225. [6]Firbank MJ, Coulthard A. Evaluation of a technique for estimation of extrocular muscle volume using 2D MRI [J]. Br J Radiol, 2000, 73(876):1282-1289. [7]Jankauskie J, Imbrasiene D. Investigations of ocular changes, extraocular muscle thickness, and eye movements in Graves’ ophthalmopathy [J]. Medicina (Kaunas), 2006, 42(11):900-903. [8]Prummel MF, Gerding MN, Zonneveld FW, et al. The usefulness of quantitative orbital magnetic resonance imaging in Graves ophthalmopathy [J]. Clin Endocrinol (Oxf), 2001, 54(2):205-209. [9]Yokoyama N, Nagataki S, Uetani M,et al. Role of magnetic resonance imaging in the assessment of disease activity in thyroidassociated ophthalmopathy [J]. Thyroid, 2002,12(3):223-227. [10]Shen S, Fong KS, Wong HB, et al. Normative measurements of the chinese extraocular musculature by high-field magnetic resonance imaging [J]. Invest Ophthalmol Vis Sci, 2010, 51(2):631-636. [11]Nagy EV, Toth J, Kaldi I, et al. Graves’ophthalmopathy: eye muscle involvement in patients with diplopia [J]. Eur J Endocrinol, 2000, 142(6):591-597. [12]Small RG. Enlargement of levator palpebrae superioris muscle fibers in Graves’ ophthalmopathy[J]. Ophthalmology, 1989,96(4):424-430. [13]Putterman AM, Urist M. Surgical treatment of upper eyelid retraction [J]. Arch Ophthalmol, 1972, 87(4):401-405. [14]Bodker FS, Putterman AM, Laris A, et al. The effect of hyperthyroidism on Müllers muscle contractility in rats [J]. Ophthal Plast Reconstr Surg,1997, 13(3):161-167. [15]Xu D, Liu Y, Xu H, et al. Repeated triamcinolone acetonide injection in the treatment of upper-lid retraction in patients with thyroid-associated ophthalmopathy [J]. Can J Ophthalmol, 2012, 47(1):34-41. [16]Frueh BR, Garber FW, Musch DC. The effects of Graves’ eye disease on levator muscle function [J]. Ophthalmic Surg, 1986, 17(3):142-145. [17]Ohnishi T, Noquchi S, Murakami N, et al. Levator palpebrae superloris muscle:MR evaluation of enlargement as a cause of upper eyelid refraction in Graves Disease [J]. Radiology, 1993, 188(1):115-118. [18]Feldon SE, Levin L. Graves’ ophthalmopathy: V. Aetiology of upper eyelid retraction in Graves ophthalmopathy [J]. Br J Ophthalmol, 1990, 74(8):484-485. [19]Ozgen A, Alp MN, Ariyurek M, et al. Quantitative CT of the orbit in Graves’disease [J]. Br J Radiol, 1999, 72(860):757-762. [20]Nishikawa M, Yoshimura M, Toyoda N, et al. Correlation orbital muscle changes evaluated by magnetic resonance imaging and thyroid-stimulating antibody in patients with Graves ophthalmopathy [J]. Acta Endocrinol, 1993, 129(3):213-219. [21]Aydin K, Güven K, Sencer S, et al. A new MRI method for the quantitative evaluation of extraocular muscle size in thyroid ophthalmopathy [J]. Neuroradiology, 2003, 45(3):184-187.
|